Table 3 Rates of PFS, rPFS, and freedom from PSA progression in the STRIVE and TERRAIN trials
Outcome | STRIVE | TERRAIN | ||||
|---|---|---|---|---|---|---|
Enzalutamide, % | Bicalutamide, % | Enzalutamide versus bicalutamide difference, % (95% CI) | Enzalutamide, % | Bicalutamide, % | Enzalutamide versus bicalutamide difference, % (95% CI) | |
PFS | ||||||
 One year | 59.5 | 9.4 | 50.1 (39.5–60.7) | 55.0 | 31.7 | 23.3 (12.6–34.0) |
 Two years | 40.0 | 4.1 | 35.9 (23.4–48.4) | 37.8 | 11.0 | 26.8 (15.0–38.7) |
rPFS | ||||||
 One year | 74.0 | 35.1 | 38.9 (24.7–53.1) | 68.2 | 58.1 | 10.1 (−2.6–22.7) |
 Two years | 56.4 | 23.2 | 33.1 (13.9–52.4) | 61.3 | 25.6 | 35.7 (18.3–53.0) |
Freedom from PSA progression | ||||||
 One year | 69.4 | 12.9 | 56.5 (45.4–67.7) | 65.1 | 18.6 | 46.5 (34.6–58.5) |
 Two years | 50.3 | 8.1 | 42.2 (27.0–57.4) | 41.3 | 10.3 | 31.0 (16.9–45.1) |